Label Changes for:
Lupron Depot (leuprolide acetate for depot suspension), 3.75 mg
January 2012
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – January 2012
ADVERSE REACTIONS
Postmarketing
Hepato-biliary disorder
- rarely reported serious liver injury

